Subcutaneous Immunoglobulin (SCIG) from Octapharma USA.
Cutaquig is a 16.5% SCIG product from Octapharma. The slightly lower concentration than 20% products may suit some patients better depending on infusion site tolerance and dose.
Cutaquig is FDA-approved for the following indications:
Cutaquig is administered subcutaneously weekly via self-infusion.
The manufacturer offers a patient support program — Octapharma Patient Resources — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.octapharma.com/us/patients.
Treatment with Cutaquig is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Administration logistics are coordinated by the office team based on the route of therapy and patient preference.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.cutaquig.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Cutaquig is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.